Progesterone Use in Heterozygous Factor V Leiden Carriers
Yes, progesterone-only contraception is safe for heterozygous Factor V Leiden carriers and represents the preferred hormonal contraceptive option when non-hormonal methods are not acceptable. 1
Key Distinction: Progesterone vs. Estrogen Risk
The critical issue is estrogen, not progesterone. Combined oral contraceptives containing estrogen increase thrombotic risk 30-fold when Factor V Leiden is present, making them absolutely contraindicated. 2, 1 In contrast, progesterone-only methods carry substantially lower thrombotic risk.
Evidence for Progesterone Safety
Progestin-only contraception shows minimal VTE risk in Factor V Leiden carriers, with an odds ratio of 5.4 (95% CI 2.5-13) compared to 20.6 for combined hormonal contraceptives—representing approximately 4-fold lower risk. 3
Except for medroxyprogesterone acetate injection, progestin-only contraception appears to be the least thrombogenic hormonal option for women carrying genetic hemostatic variations. 3
The baseline annual VTE incidence in heterozygous Factor V Leiden carriers is only 0.45%, with lifetime risk approximately 10%. 1, 4
Recommended Contraceptive Hierarchy
For heterozygous Factor V Leiden carriers:
- First-line: Non-hormonal methods (copper IUD) remain safest 5
- Second-line: Progesterone-only options are acceptable when non-hormonal methods fail:
- Progesterone IUD (levonorgestrel)
- Progesterone-only pills
- Etonogestrel implant
- Avoid: Medroxyprogesterone acetate injection (OR 2.2 for VTE) 3
- Absolutely contraindicated: Combined estrogen-containing contraceptives 2, 1
Critical Caveats
Prior VTE history is an absolute contraindication to any hormonal contraception, including progesterone-only methods. 1
One case report documented isolated pulmonary embolism in a Factor V Leiden carrier using progesterone IUD, though causality remains uncertain given the low baseline risk. 5
Routine screening for Factor V Leiden before prescribing progesterone-only contraception is not recommended in asymptomatic women without personal or family history of thromboembolism. 2
Postmenopausal Hormone Therapy Context
If the question pertains to postmenopausal progesterone therapy:
Transdermal estrogen with progesterone shows no increased VTE risk (OR 0.9,95% CI 0.4-2.1) in Factor V Leiden carriers, unlike oral estrogen which increases risk 2- to 6-fold. 1
Oral hormone replacement therapy (estrogen with or without progesterone) increases VTE risk threefold and should be avoided. 1, 6
Prior VTE or active thrombotic conditions remain absolute contraindications even for transdermal formulations. 1